Back to Search
Start Over
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
- Source :
- Journal of Thoracic Oncology; 20240101, Issue: Preprints
- Publication Year :
- 2024
-
Abstract
- Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing responses. Assessment of KRASand TP53mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap.
Details
- Language :
- English
- ISSN :
- 15560864 and 15561380
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs64884575
- Full Text :
- https://doi.org/10.1016/j.jtho.2023.12.015